Table 3.
HIV related clinical characteristics of the study participants by nutritional status (N = 350)
| Variable | N (%) | Nutritional status | p value | ||
|---|---|---|---|---|---|
| Underweight N = 64 |
Normal N = 149 |
Overweight/Obese N = 137 |
|||
| ART regimen | 0.17 | ||||
| Non-zidovudine based regimen | 215 (61.4) | 39 (18.1) | 84 (39.1) | 92 (42.8) | |
| Zidovudine based regimen | 135 (38.6) | 25 (18.5) | 65 (48.1) | 45 (33.3) | |
| ART duration Median (range) | 48 (6, 168) | 0.12 | |||
| ≥ 24 months | 234 (66.9) | 49 (20.9) | 100 (42.7) | 85 (36.3) | |
| < 24 months | 116 (33.1) | 15 (12.9) | 49 (42.2) | 52 (44.8) | |
| Opportunistic infection | 0.15 | ||||
| No | 338 (96.6) | 61 (18.0) | 143 (42.3) | 134 (39.6) | |
| HCV | 7 (2.0) | 0 (0.0) | 5 (71.4) | 2 (28.6) | |
| Tuberculosis | 4 (1.1) | 2 (50.0) | 1 (25.0) | 1 (25.0) | |
| Syphilis | 1 (0.3) | 1 (100.0) | 0 (0.0) | 0 (0.0) | |
| WHO stage | 0.04 | ||||
| Stage I | 153 (43.7) | 21 (13.7) | 64 (41.8) | 68 (44.4) | |
| Stage II | 81 (23.1) | 25 (30.9) | 32 (39.5) | 24 (29.6) | |
| Stage III | 80 (22.9) | 13 (16.3) | 36 (45.0) | 31 (38.8) | |
| Stage IV | 36 (10.3) | 5 (13.9) | 17 (47.2) | 14 (38.9) | |
| CD4 count Median (range) | 368.5 (13, 1713) | 382 (5, 1468) | 440 (21, 1695) | 0.69 | |
| Less than 200 cells/mm3 | 51 (14.6) | 12 (23.5) | 20 (39.2) | 19 (37.3) | |
| Between 200 to 500 cells/mm3 | 176 (50.3) | 34 (19.3) | 75 (42.6) | 67 (38.1) | |
| Greater than 500 cells/ mm3 | 123 (35.1) | 18 (14.6) | 54 (43.9) | 51 (41.5) | |
| Hemoglobin level | 0.02 | ||||
| Non-anemic | 238 (68) | 38 (16.0) | 92 (38.7) | 108 (45.4) | |
| Anemic | 112 (32) | 26 (23.2) | 57 (50.9) | 29 (25.9) | |